Xu Jialing, Huang Bin, Zhu Yanhua, Shi Jianping, Zhou Qiang
Departments of Medical Oncology, The First People's Hospital of Xiaoshan District, Hangzhou, Zhejiang, China.
Department of Pathology, The First People's Hospital of Xiaoshan District, Hangzhou, Zhejiang, China.
Front Immunol. 2025 Jul 21;16:1636575. doi: 10.3389/fimmu.2025.1636575. eCollection 2025.
This report describes a 56-year-old female diagnosed with lymphoepithelioma-like carcinoma with carcinosarcoma of the endometrium (LELCCSE). She experienced vaginal bleeding and lower abdominal discomfort without any obvious cause following six years of menopause. She sought treatment at our hospital in Hangzhou, China. An ultrasound examination revealed a hypoechoic mass within the uterus. Subsequently, a biopsy confirmed it as lymphoepithelioma-like carcinoma (LELC) with carcinosarcoma.The patient underwent a total hysterectomy, bilateral salpingo-oophorectomy, and associated lymphadenectomy. The postoperative pathology suggested LELC complicated with carcinosarcoma and an IIC grade by the 2023 FIGO staging system. She received adjuvant chemotherapy and radiotherapy without any molecular testing due to her financial constraints. A gene which encodes the catalytic subunit of DNA polymerase epsilon(POLE) mutation was found by the retrospective molecular testing; however, no recurrence or metastasis occurred after 12 follow-up months.
本报告描述了一名56岁女性,被诊断为子宫内膜淋巴上皮瘤样癌伴肉瘤样癌(LELCCSE)。她在绝经六年之后,无明显诱因出现阴道出血和下腹部不适。她在中国杭州的我院寻求治疗。超声检查显示子宫内有一个低回声肿块。随后,活检证实为伴有肉瘤样癌的淋巴上皮瘤样癌(LELC)。患者接受了全子宫切除术、双侧输卵管卵巢切除术及相关淋巴结清扫术。术后病理提示LELC合并肉瘤样癌,根据2023年FIGO分期系统为II C期。由于经济限制,她未进行任何分子检测便接受了辅助化疗和放疗。回顾性分子检测发现了一个编码DNA聚合酶ε(POLE)催化亚基的基因突变;然而,随访12个月后未出现复发或转移。